A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease

Journal of Rheumatology

Volumn 25, Issue 7, 1998, Pages 1325-1329

  Várai, György ^e   Earle, Linda ^b   Jimenez, Sergio A ^c   Steiner, Robert M ^d   Varga, John ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b Department of Medicine Div Pulmon Med and Critical Care

^c Department of Medicine Division of Rheumatology

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e Section of Rheumatology M/C 733 Univ Illinois Chicago Coll of Med ^*

Author keywords

Cyclophosphamide; Interstitial lung disease; Systemic sclerosis

Indexed keywords

CYCLOPHOSPHAMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG INTERMITTENT THERAPY; DYSPNEA; FEMALE; HUMAN; LUNG FIBROSIS; MALE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

EID: 2642705882     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Lee P, Langevitz P, Alderdice CA, et al. Mortality in systemic sclerosis (scleroderma). Q J Med 1992;82:139-48.
2. Furst DE, Clements PJ, Hillis S, et al. Immunosuppression with chlorambucil, versus placebo, for scleroderma. Arthritis Rheum 1989;32:584-93.
3. Casas JA, Saway PA, Villarreal I, et al. 5-fluorouracil in the treatment of scleroderma: a randomized, double blind, placebo controlled international collaborative study. Ann Rheum Dis 1990;49:926-8.
4. Gruber BL, Kaufman LD. A double-blind randomized controlled trial of ketotifen versus placebo in early diffuse scleroderma. Arthritis Rheum 1991;34:362-6.
5. De Clerck LS, Dequeker J, Francx L, Demedts M. D-penicillamine therapy and interstitial lung disease in scleroderma. A long-term follow-up study. Arthritis Rheum 1987;30:643-50.
6. Jimenez AJ, Sigal SH. A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine. J Rheumatol 1991;18:1496-503.
7. Akesson A, Scheja A, Lundin A, Wollheim FA. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994;37:729-35.
8. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993;20:834-44.
9. Steen VD, Lanz JK, Conte C, Owens GR, Medsger TA Jr. Therapy for severe interstitial lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1290-6.
10. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis. Arthritis Rheum 1980;23:581-90.
11. Le Roy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
12. Watters LC, King TE, Schwarz MI, Waldron JA, Stanford RE, Cherniak RM. A clinical, radiographic and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986;133:97-103.
13. Morris AH, Karner RE, Crapo RO, et al. Clinical pulmonary function testing. A manual of uniform laboratory procedures. 2nd edition. Intermountain Thoracic Society, 1984.
14. Goldman HI, Becklake MR. Respiratory function tests: normal values at median altitudes and prediction of normal results. Am Rev Tuberculosis 1959;79:457.
15. Ettensohn DB, Jankowski MJ, Duncan PG, Lalor PA. Bronchoalveolar lavage in the normal volunteer subject. I. Technical aspects and intersubject variability. Chest 1988;94:275-80.
16. Wechsler RJ, Steiner RM, Spirn PW, et al. The relationship of thoracic lymphadenopathy to pulmonary interstitial disease in diffuse and limited systemic sclerosis: CT findings. Am J Roentgenol 1996;167:101-4.